
Afatin 40mg Tablet
Marketer
BDR Pharmaceuticals Internationals Pvt
Salt Composition
Afatinib dimaleate (40mg)
Overview Afatin 40mg Tablet
EGF receptor inhibitor, Oncaspar 40mg tablets, combats non-small cell lung cancer in adults with specific EGFR gene mutations. Administer on an empty stomach, consistently at the same time daily for optimal efficacy. Dosage and frequency are determined by your physician based on your condition and may adjust over time; adhere strictly to prescribed instructions. Incorrect usage or overdose may lead to severe adverse reactions. Therapeutic effects might not be apparent for weeks or months; discontinue only under medical guidance. Common side effects involve diarrhea (which can be severe, requiring prompt medical attention and hydration), skin rash, dryness, and nausea. Regular blood tests may be recommended. Photosensitivity is possible; utilize sunscreen and protective clothing outdoors. Report any ocular discomfort (pain, redness, dryness). Prior to commencement, disclose any respiratory, hepatic, or renal impairments, or concurrent use of anti-infective medications. Interactions with other drugs are possible; ensure your healthcare provider has a complete medication list. This medication is contraindicated during pregnancy and lactation; reliable contraception is crucial for female patients undergoing treatment.
Primary Ingredients of Afatin 40mg Tablet
No information provided. Please provide the text you wish to be rewritten.
Uses of Afatin 40mg Tablet
Lung cancer (excluding small cell types)
Major Benefits of Afatin 40mg Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Afatin 40mg Tablets should be administered on an empty stomach.
Common Side effects of Afatin 40mg Tablet:
- Diarrhea
- Rash
- Dry skin
- Nausea
- Vomiting
- Loss of appetite
- Itching
- Stomatitis (Inflammation of the mouth)
- Nail disorder
How to use Afatin 40mg Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the 40mg Afatin tablet whole; avoid chewing, crushing, or breaking it. Administer on an empty stomach.
How Afatin 40mg Tablet works:
Afatin 40mg tablets are an anti-neoplastic agent. Their mechanism of action involves targeted inhibition of enzyme receptors—specifically EGFR, HER2, and HER4—crucial for cancer cell proliferation. This blockage disrupts vital signaling pathways, thereby hindering or reducing the spread of cancerous growth.
SAFETY ADVICE
AlcoholSAFE
Afatin 40mg Tablet use alongside alcohol consumption presents no known adverse reactions.
PregnancyCONSULT YOUR DOCTOR
Using Afatin 40mg tablets during pregnancy poses a confirmed risk to the fetus. Therefore, it's contraindicated. Nevertheless, a physician might exceptionally prescribe it in critical circumstances where the potential benefits outweigh the known hazards. Always seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Use of Afatin 40mg tablets while breastfeeding is likely inadvisable. Preliminary human evidence indicates potential transfer to breast milk, posing a possible risk to the infant.
DrivingCONSULT YOUR DOCTOR
Afatin 40mg Tablet's effect on driving ability is undetermined. Refrain from operating a vehicle if you encounter symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
Afatin 40mg tablets are likely safe for individuals with kidney impairment. Existing evidence indicates dose modification may be unnecessary, however, physician consultation is advised.
LiverSAFE IF PRESCRIBED
Afatin 40mg tablets are likely safe for individuals with hepatic impairment. Current evidence indicates dose modification may not be necessary. However, physician consultation is recommended.
What if you forget to take Afatin 40mg Tablet :
Omit any missed Afatin 40mg Tablet dose and resume your regular medication regimen. Avoid taking a double dose.
Facts to Know About Afatin 40mg Tablet
| Label | Value |
|---|---|
| Chemical Classification | Quinazoline-Butenamide Hybrid |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Action Class | Kinase inhibitors targeting tyrosine |
